These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17215726)

  • 1. Treatment of vascular dementia and vascular cognitive impairment.
    Demaerschalk BM; Wingerchuk DM
    Neurologist; 2007 Jan; 13(1):37-41. PubMed ID: 17215726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy.
    Tang J; Wingerchuk DM; Crum BA; Rubin DI; Demaerschalk BM
    Neurologist; 2007 May; 13(3):164-7. PubMed ID: 17495764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.
    Erkinjuntti T; Román G; Gauthier S
    J Neurol Sci; 2004 Nov; 226(1-2):63-6. PubMed ID: 15537522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia.
    Almaraz AC; Driver-Dunckley ED; Woodruff BK; Wellik KE; Caselli RJ; Demaerschalk BM; Adler CH; Caviness JN; Wingerchuk DM
    Neurologist; 2009 Jul; 15(4):234-7. PubMed ID: 19590387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
    Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current concepts in vascular cognitive impairment and pharmacotherapeutic implications.
    Rojas-Fernandez CH; Moorhouse P
    Ann Pharmacother; 2009 Jul; 43(7):1310-23. PubMed ID: 19584390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Modern therapy for dementia].
    Padberg F; Möller HJ; Bottlender R; Hampel H
    MMW Fortschr Med; 2005 May; 147 Spec No 2():71-4, 76-7. PubMed ID: 15968877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The action of memantine on the cognitive disorders of patients with dementia: reflections following two years' experience in Spain].
    Robles-Bayón A
    Rev Neurol; 2006 Mar 1-15; 42(5):288-96. PubMed ID: 16538592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is donepezil effective for multiple sclerosis-related cognitive dysfunction? A critically appraised topic.
    O'Carroll CB; Woodruff BK; Locke DE; Hoffman-Snyder CR; Wellik KE; Thaera GM; Demaerschalk BM; Wingerchuk DM
    Neurologist; 2012 Jan; 18(1):51-4. PubMed ID: 22217618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine for the prevention and treatment of postdural puncture headache: debunking the myth.
    Halker RB; Demaerschalk BM; Wellik KE; Wingerchuk DM; Rubin DI; Crum BA; Dodick DW
    Neurologist; 2007 Sep; 13(5):323-7. PubMed ID: 17848873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When should drug treatment be started for people with dementia?
    Singh B; O'Brien JT
    Maturitas; 2009 Mar; 62(3):230-4. PubMed ID: 19201114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis.
    Porcel J; Montalban X
    J Neurol Sci; 2006 Jun; 245(1-2):177-81. PubMed ID: 16674980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does prophylactic postoperative hypervolemic therapy prevent cerebral vasospasm and improve clinical outcome after aneurysmal subarachnoid hemorrhage?
    Capampangan DJ; Wellik KE; Aguilar MI; Demaerschalk BM; Wingerchuk DM
    Neurologist; 2008 Nov; 14(6):395-8. PubMed ID: 19008746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany.
    Hoffmann F; van den Bussche H; Glaeske G; Kaduszkiewicz H
    Int Clin Psychopharmacol; 2010 Jan; 25(1):29-36. PubMed ID: 19934763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine treatment of cognitive impairment in bipolar disorder: four cases.
    Schrauwen E; Ghaemi SN
    Bipolar Disord; 2006 Apr; 8(2):196-9. PubMed ID: 16542191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migraine with aura is a risk factor for cardiovascular and cerebrovascular disease: a critically appraised topic.
    Wingerchuk DM; Spencer B; Dodick DW; Demaerschalk BM
    Neurologist; 2007 Jul; 13(4):231-3. PubMed ID: 17622918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of dementia and cognitive impairment: what can we learn from the Cochrane Library.
    Bereczki D; Szatmári S
    J Neurol Sci; 2009 Aug; 283(1-2):207-10. PubMed ID: 19268303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.